Ruchlemer R, Ben-Ami R, Bar-Meir M, et al. - Researchers conducted this investigation to add a systematic data collection to accumulate invasive-fungal-diseases (IFD)-associated ibrutinib reports in chronic lymphocytic leukemia and non-Hodgkin lymphoma patients and to determine IFD's prevalence and clinical characteristics in this setting. From 22 centers in 8 countries, 35 patients with IFD were reported. Before the IFD onset, the median duration of ibrutinib treatment was 45 days. According to this retrospective, multi-national survey, pulmonary involvement occurred in 69% of patients, cranial in 60%, and disseminated disease in 60%. Findings revealed that the prevalence of IFD in ibrutinib-treated patients with chronic lymphocytic leukemia/non-Hodgkin lymphoma seems to be higher than expected. These patients often have unusual clinical characteristics. In this study, mortality from IFD was high, indicating that further studies are urgently required to identify patients at risk for IFD associated with ibrutinib.